Standard BioTools

Standard BioTools Working Capital

The Working Capital of Standard BioTools (LAB) as of Sep 21, 2026 is 371.47 M USD. In the previous year, Working Capital was 261.54 M USD — a change of 42.03% (higher).

Working Capital

371.47 MUSD

YoY

42.03%

Last updated:

Working Capital of Standard BioTools is 2026 371.47 M USD. Working Capital of Standard BioTools was 2025 261.54 M USD. It decreases by 42.03% higher compared to the previous year.
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Working Capital of Standard BioTools is 371.47 M USD in 2026.

Working Capital of Standard BioTools changed from 261.54 M USD to 371.47 M USD, representing a 42.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools